Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology (ALGN) to $300 from $250 and reiterates an Overweight rating on the shares. The maker of the Invisalign system closed yesterday up $1.40 to $253.73.

Following a call with an industry expert who runs a dental consultancy, the analyst is more constructive on the competitive advantage of Align's products and business model. Align appears to be the only company that can simultaneously treat complex cases best and produce enough volume to go after "low-hanging fruit on the simple cases,"

O'Brien tells investors in a research note. The expert told the analyst that there is not a single case Invisalign cannot do today. O'Brien continues to view the company as one of the most compelling growth stories in all of medical technology.